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Introduction: Studies from selected candidate genes suggest that
single-nucleotide polymorphisms (SNPs) involved in glutathione
metabolism, DNA repair, or inflammatory responses may affect
overall survival (OS) in stages I to II or low-stage non-small cell
lung cancer (LS-NSCLC); however, results are inconclusive. In this
study, we took a systematic pathway-based approach to simultane-
ously evaluate the impact of genetic variation from these three
pathways on OS after LS-NSCLC diagnosis.
Methods: DNA from 647 patients with LS-NSCLC was geno-
typed for 480 SNPs (tag-SNPs) tagging 57 genes from the three
candidate pathways. Associations of tag-SNPs with OS were
assessed at the individual SNP and whole gene levels, adjusting
for age, tumor stage, surgery type, and adjuvant therapy. The
genotype combinations of the SNPs associated with OS were also
estimated.
Results: Among the 412 tag-SNPs that were successfully genotyped
and passed quality assessments, 28 showed association with OS
(p  0.05). Two of the 28 were estimated to have less than a 20%
chance of being false positives (rs3768490 in GSTM5: p  1.32 
104, q 0.06; rs1729786 in ABCC4: p 9.25 104, q 0.20).
Gene-based analysis suggested that in addition to GSTM5 and
ABCC4, variation in two other genes, PTGS2 and GSTA2, was also
associated with OS.
Conclusions: We describe further evidence that variations in genes
involved in the glutathione and inflammatory response pathways are
associated with OS in patients with LS-NSCLC. Further studies are
warranted to verify our findings and elucidate their functional
mechanisms and clinical utility leading to improved survival for
patients with lung cancer.
Key Words: Glutathione metabolism, DNA repair, Inflammation
response, Genetic polymorphisms, Non-small cell lung cancer, Sur-
vival analysis.
(J Thorac Oncol. 2011;6: 1488–1495)
Lung cancer is the leading cause of cancer death of men andwomen combined worldwide,1 and approximately 80% of
lung cancer cases are classified histologically as non-small
cell lung cancer (NSCLC). For patients with low-stage
(stages I–II) NSCLC (LS-NSCLC), surgical resection is the
standard primary treatment, and a definitive role for adjuvant
therapy has yet to be established.2 The 5-year survival rates
after surgical resection of LS-NSCLC range from 30 to 70%3;
the use of adjuvant therapy (pre or postsurgery) or during
cancer recurrence may improve survival, particularly for
those who responded well to the initial treatment. To our best
knowledge, however, no prognostic factors or biomarkers are
available to accurately stratify the patients to optimal treat-
ment plans. Evidence has shown that genetic factors, such as
variants of the genes involved in the glutathione metabolism,
DNA repair and inflammatory response pathways, may im-
pact the prognosis of patients with NSCLC,4–10 which re-
quires more systematic confirmation and mechanistic inves-
tigation.
The glutathione pathway is comprised of enzymes
responsible for glutathione synthesis, redox, glutathione con-
jugation, and transporters that remove glutathione conjugates
from cells. Studies have shown that genes in this system are
highly polymorphic and that many are correlated with en-
zyme activities of the pathway and can alter responses in
individuals exposed to certain environmental hazards.11 The
DNA repair system has a critical role in protecting the
genome from insults caused by carcinogenic agents.12 Poly-
morphisms which affect protein activity in DNA repair genes
may alter the efficiency of these processes and lead to genetic
instability. As a double-edged sword, they may affect the
effectiveness of chemotherapy agents targeting DNA.13,14
Inflammatory responses to environmental exposures, such as
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tobacco smoke and cytotoxic agents, may play a role in lung
carcinogenesis and prognosis after disease onset.10 Mutations
or genetic variants of the genes involved in this pathway may
perturb the balance between tumor growth and host response
and thereby influence disease progression. A number of
studies in recent years have demonstrated the significant role
of genetic variation in the glutathione metabolism, DNA
repair, and inflammatory response pathways in the overall
survival (OS) of patients with NSCLC,10,12,14–22 but contro-
versies remain. The majority of these studies focused on
advanced-stage NSCLC. Knowledge for LS-NSCLC is very
limited.
The primary aim of our study was to systematically
evaluate the potential effects of individual genetic variants in
selected genes from the glutathione metabolism, DNA repair,
and inflammatory response pathways on OS in LS-NSCLC.
A secondary aim was to use the identified risk variants to
construct an OS prediction model.
PATIENTS AND METHODS
Patient Cohort
Patients with lung cancer with LS-NSCLC diagnosed
and treated with surgical resection at Mayo Clinic from 1997
to 2007 were included in this study. Detailed descriptions of
patient identification, enrollment, blood collection, and fol-
low-up have been published previously.3 Briefly, each subject
was identified through the Mayo Clinic pathologic diagnostic
(Co-Path) system, and patient medical records were ab-
stracted by a trained nurse to obtain sex, age at diagnosis,
history of tobacco exposure use, lung cancer stage and his-
tological cell type, surgery type, adjuvant therapies, and the
presence of comorbidities at diagnosis. The abstracted co-
morbid conditions included a range of major illnesses, such
as other cancers, cardiovascular diseases, diabetes, hyperten-
sion, chronic bronchitis, and chronic obstructive pulmonary
disease. For purposes of our analyses, we classified patients
according to whether any comorbidity was present at diag-
nosis. Never smokers were defined as individuals who
smoked fewer than 100 cigarettes during their lifetimes;
former smokers were those who had quit smoking for 6
months or more before their lung cancer diagnosis; and
current smokers were those who were smoking at the time of
diagnosis. A blood sample was collected from all participants
after informed consent was obtained. Survival status and
cause of death were determined by reviewing the Mayo
Clinic registration database and medical records, obtaining
correspondence from patients’ next-of-kin, and by monitor-
ing a variety of other sources, including death certificates,
obituary documents, the Mayo Clinic Tumor Registry, and
the Social Security Death Index website. Eight percent of
non-white patients were excluded from this study to minimize
population heterogeneity. This study was reviewed and ap-
proved by the Mayo Clinic Institutional Review Board.
Single-Nucleotide Polymorphism Selection and
Genotyping Procedure
We selected 29 genes from the glutathione metabolism
pathway, as described previously.4 Additionally, 20 genes from
the DNA repair pathway and eight key genes from the inflam-
matory response pathway were included in this study, after a
review of the literature for evidence of genetic associations with
treatment response or survival in lung or other cancers. Tag-single-
nucleotide polymorphisms (tag-SNPs) within these genes were
selected based on HapMap data (http://www.hapmap.org/) of 60
unrelated white subjects (Release 22/Phase II on NCBI B36) by
Haploview (http://www.broad.mit.edu/mpg/haploview/). Candi-
date SNPs meeting the quality thresholds of having 75% of
individuals with genotypes, Hardy-Weinberg p values more
than 0.001, and minor allele frequencies more than 0.001
were identified from the candidate genes. Tag-SNPs for each
gene were selected using an r2 threshold of 0.8,23 ignoring
SNPs more than 500 kb apart.
Four hundred seventy tag-SNPs, 267 from the glutathi-
one metabolism pathway, 152 from the DNA repair pathway,
and 51 from the inflammatory response pathway were geno-
typed using a custom-designed Illumina GoldenGate panel.
Quality control was implemented in multiple steps, as described
previously.24 In brief, SNPs were excluded from further analysis
if they had call rates less than 95% or Hardy-Weinberg equilib-
rium p values less than 105 or minor allele frequencies less
than 0.01 in this study population.
Statistical Analysis
The clinical characteristics of the patients were sum-
marized by person-years of follow-up, and 5-year survival
was estimated, with corresponding 95% confidence intervals
(CIs) using the Kaplan-Meier approach. Demographic and
clinical variables were assessed for associations with OS in
univariate and multivariate Cox proportional hazards regres-
sion models. These models were assessed to verify that the
data conformed to assumptions of regression approach. To
identify the subset of demographic and clinical factors as
adjustment variables (covariates) in genetic association tests,
we performed a stepwise selection process using Cox pro-
portional hazards regression and retained variables whose p
values were less than 0.05.
For each SNP that passed quality control thresholds, we
used a Cox regression model to assess the associations
between the SNP genotypes and OS, while adjusting for
covariates. A genetic model-free approach was used, where
the heterozygote and rare homozygote genotypes were simul-
taneously compared with the reference genotype (common
homozygote). We extracted hazard ratios (HRs), 95% CIs,
and two degrees of freedom p values, and computed q values
corresponding to the p values from each of the candidate
SNPs to assess the false discovery rates.25
Gene-based association tests were also used to obtain
additional information about the potential effects of the se-
lected genes in glutathione metabolism, DNA repair, and
inflammatory response pathways on OS. A principal compo-
nents analysis was performed on the tag-SNP genotypes from
each gene to identify uncorrelated linear combinations of
tag-SNP data that captured at least 80% of the variability
present in the tag-SNPs within the gene. The primary genetic
coding was based on a log-additive genetic model in which
SNP genotypes were coded to reflect the number of minor
alleles carried by each individual; parallel analyses were
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performed for dominant and recessive genetic models. The
identified principal components were used to perform an
omnibus test of significance for the association between each
of the candidate genes and OS in multivariable Cox propor-
tional hazards regression models. p values for the global tests
were obtained, along with outcome summaries of the princi-
pal components analysis.26,27
We tested the combined effects of the tag-SNPs with
false discovery rates (q values) no larger than 20%. We first
formed all possible pairs of genotypes of the multiple signif-
icant tag-SNPs and compared all genotype combinations to
the reference combination of the major allele homozygotes of
the component SNPs. We also identified the at-risk genotypes
and formed a score that reflected the ordinal number of at-risk
genotypes carried by each subject. HRs and 95% CIs asso-
ciated with these at-risk genotype combinations were esti-
mated, both individually and as an ordinal trend. All analyses
were carried out using SAS (SAS Institute, Inc., Cary, NC)
and R (http://www.r-project.org/) software systems.
RESULTS
Demographic and Clinical Characteristics
Demographic and clinical characteristics of 647 pa-
tients with stages I and II NSCLC are listed in Table 1. The
average age of all patients was 66.6 years, with slightly more
men (53.8%) than women (46.2%), and 82% were stage I at
the time of diagnosis. By the time of analysis, more than one-
half of the subjects were still living, with a median follow-up
time of 7.06 years. The 5-year OS in this cohort was 73.6%
(95% CI  70.0–76.9%). In univariate assessments, five
variables were significantly associated with OS (p values 
TABLE 1. Univariate and Multivariate Analyses for Survival by Demographic and Clinical Characteristics
Characteristics
Total (%),
N  647
Person-Years
of Follow-Up
Dead,
N  279
Univariate Analysis Multivariate Analysis
HR (95% CI) p HR (95% CI) p
Sex
Female 299 (46.2) 1764.1 117 1.00 (reference) 1.00 (reference)
Male 348 (53.8) 1980.1 162 1.22 (0.96–1.55) 0.11 1.08 (0.83–1.39) 5.66  101
Age at diagnosis
(mean  SD)
66.6  8.8 68.4  8.8 1.03 (1.02–1.05) 1.96  105 1.04 (1.03–1.06) 7.55  107
Smoking status
Never smokers 102 (15.8) 589.4 37 1.00 (reference) 1.00 (reference)
Former smokers 350 (54.1) 2051.0 162 1.20 (0.84–1.71) 3.27  101 0.89 (0.60–1.31) 5.49  101
Current smokers 195 (30.1) 1105.7 80 1.14 (0.77–1.68) 5.10  101 0.95 (0.63–1.44) 8.24  101
Surgery subtype
Lobectomy 435 (67.2) 2614.4 168 1.00 (reference) 1.00 (reference)
More extensive
resection
110 (17.0) 607.9 58 1.48 (1.10–2.00) 1.05  102 1.14 (0.81–1.60) 4.59  101
Others 102 (15.8) 524.3 53 1.61 (1.18–2.20) 2.46  103 1.51 (1.10–2.07) 1.17  102
Adjuvant therapy
Surgery alone 455 (70.3) 2837.4 160 1.00 (reference) 1.00 (reference)
Surgery and
chemotherapy
99 (15.3) 452.1 55 2.37 (1.74–3.23) 4.95  108 2.87 (1.91–3.65) 3.65  109
Surgery and
radiation
28 (4.3) 143.5 18 2.30 (1.41–3.76) 8.07  104 1.19 (1.14–3.09) 1.33  102
Surgery and chemo 
radiation
65 (10.0) 313.3 46 2.72 (1.96–3.79) 2.43  109 12.3 (2.03–4.05) 1.84  109
Lung cancer subtype
Adenocarcinoma 383 (59.2) 2320.5 146 1.00 (reference) 1.00 (reference)
Squamous 184 (28.4) 1026.4 94 1.46 (1.12–1.89) 4.62  103 1.19 (0.90–1.59) 2.21  101
Others 80 (12.4) 420.3 39 1.57 (1.10–2.24) 1.26  102 1.23 (0.85–1.79) 2.62  101
Lung cancer stage
IA 309 (47.8) 1898.4 106 1.00 (reference) 1.00 (reference)
IB 221 (34.2) 1246.4 112 1.57 (1.21–2.05) 8.51  104 1.34 (1.01–1.76) 4.00  102
IIA 29 (4.5) 170.4 12 1.24 (0.68–2.25) 4.88  101 1.35 (0.74–2.46) 3.12  101
IIB 88 (13.6) 431.2 49 2.07 (1.48–2.91) 2.55  105 1.67 (1.13–2.48) 1.01  102
Comorbidity at
diagnosis
No 141 (21.8) 824.9 54 1.00 (reference) 1.00 (reference)
Yes 506 (78.2) 2919.6 225 1.15 (0.86–1.55) 3.50  101 1.09 (0.81–1.48) 5.71  101
Values are presented as a number (percent) unless otherwise indicated; age at diagnosis, surgery subtype, adjuvant therapy, and lung cancer stage were identified as adjustment
variables for genetic association tests.
HR, hazard ratio; CI, confidence interval.
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0.05), whereas in our multivariate analysis, four variables
were simultaneously associated with OS: age at diagnosis,
surgery subtype, adjuvant therapy, and stage; they were
considered to be potential confounders and were included as
adjustment variables in the SNP- and gene-based analyses.
Assessments of the multivariable models did not identify
large deviations from the assumptions required by the Cox
proportional hazards regression model.
Single SNP Analysis
From 57 candidate genes in the three pathways of
interest, we genotyped 480 tag-SNPs. Thirty-two of the 480
tag-SNPs were failed by the genotyping center; nine had a
minor allele frequency less than 0.01; 11 were monomorphic;
and 16 were not in Hardy-Weinberg equilibrium (nine had
copy number variant issues). This resulted in a total of 412
tag-SNPs for analysis. Supplementary Table 1 (Supplemen-
tary Digital Content 1, http://links.lww.com/JTO/A94) con-
tains a listing of all the SNPs that were genotyped in this study.
The average call rate for these SNPs was 99.5%, and the
concordance between control DNA samples was 100%. No
individual sample failed genotyping for this panel of SNPs.
Twenty-eight SNPs, distributed among 20 genes, had p
values less than 0.05 for the genetic model-free tests. After
estimating q values to evaluate the probability of false-positive
findings, 2 of the 28 had q values no larger than 0.20: rs3768490
(p value  1.32  104, q value  0.06) in the GSTM5 gene
and rs1729786 (p value  9.25  104, q value  0.20) in the
ABCC4 gene. The results of the SNP-based association tests are
listed in Supplementary Table 1 (Supplemental Digital Content
1, http://links.lww.com/JTO/A94).
Gene-Based Analysis
Gene-based association results are presented in Sup-
plementary Table 2 (Supplemental Digital Content 2,
http://links.lww.com/JTO/A95). A total of 51 genes were
tested using the principal components approach described in
the methods section. The two genes containing the individu-
ally significant SNPs, GSTM5 and ABCC4, were both con-
firmed to be significantly associated with OS (p values 
2.22  103 and 1.46  102 for GSTM5 and ABCC4,
respectively). In the whole-gene tests, both PTGS2 and
GSTA2 were also suggestively associated with OS (p val-
ues  2.11  102 and 4.32  102 for PTGS2 and GSTA2,
respectively).
Cumulative Risk Assessment
The risk associations arising from combining data from
the two independent high-risk tag-SNPs, which were identi-
fied in the SNP-based analyses and confirmed by gene-based
analysis, are presented in Tables 3 and 4. First, all combina-
tions of the two genotypes were formed, and specific HR
estimates were obtained; the combination of the common
homozygote of the two SNPs was the reference group; age at
diagnosis, lung cancer stage, surgery subtype, and adjuvant
therapy were the adjustment variables. The HR estimates
ranged from 0.53 to 2.06 (Table 3): the lowest HR was
observed in patients with the A/A genotype for rs3768490
and G/G genotype for rs1729786, whereas, the highest HR
was observed in patients with the A/C genotype for
rs3768490 and A/A genotype for rs1729786. When compar-
ing this saturated model to the model that only included the
main effects of the SNPs, no significant interaction was
detected between the two SNPs (p  0.90). Figure 1 depicts
the adjusted survival curves for the patients with different
combinations of the top two candidate SNPs. There are nine
survival curves, one for each of the nine genotype combina-
tions between rs3768490 and rs1729786. Compared with the
reference group (CC/GG), five genotype combination groups
showed significant difference, four with worse and one with
better survival (Table 3 and Figure 1). For comparison, we
also provided the unadjusted Kaplan-Meier survival curves
for the nine combinations in Supplemental Figure 1 (Supple-
mental Digital Content 3, http://links.lww.com/JTO/A96).
In addition to examining the simultaneous inclusion of
both SNPs in a single model, we also created a risk score
based on the number of high-risk alleles. The results sug-
gested that rs3768490 acted in a recessive mode, whereas
rs1729786 followed an ordinal pattern. Therefore, corre-
sponding to rs3768490, individuals with 0 and one copy of
the minor allele received a score of 0, whereas individuals
TABLE 2. Significant SNPs After Adjusting for Clinical Variables
Characteristics
Total (%),
N  647
Person-Years
of Follow-Up
Dead,
N  279
Univariate Analysis Multivariate Analysisa
HR (95% CI) p HR (95% CI) p
RS3768490 (GSTM5)
CC 272 (42.0) 1591.2 118 1.00 (reference) 2.00  104 1.00 (reference) 1.32  104
AC 281 (43.4) 1555.0 137 1.21 (0.94–1.55) 1.19 (0.92–1.53)
AA 94 (14.5) 603.0 24 0.51 (0.33–0.80) 0.53 (0.34–0.83)
RS1729786 (ABCC4)b
GG 217 (33.6) 1324.1 79 1.00 (reference) 1.90  103 1.00 (reference) 9.25  104
AG 323 (50.0) 1815.3 146 1.43 (1.08–1.89) 1.36 (1.03–1.81)
AA 106 (16.4) 607.8 54 1.85 (1.30–2.63) 1.73 (1.22–1.47)
Values are presented as a number (%) unless otherwise indicated.
a Age at diagnosis, surgery subtype, adjuvant therapy, and lung cancer stage were selected as adjustment variables in genetic association tests.
b N  646 (1 with missing genotype).
SNP, single-nucleotide polymorphism; HR, hazard ratio; CI, confidence interval.
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carrying two copies received a score of 2; the risk score
corresponding to rs1729786 was the number of the minor
alleles carried by the patient; and the final risk score was the
sum of component risk scores from both SNPs (Table 4).
These risk scores ranged from 0 to 4, with increasing values
of the risk score being associated with increased risk of death;
specifically, each increment of 1 unit in risk score suggests a
1.37-fold higher risk of dying post LS-NSCLC diagnosis with
adjustment of four potential confounders. Figure 2 illustrates
the adjusted survival curves for patients with the different risk
scores (Supplementary Figure 2, Supplemental Digital Con-
tent 4, http://links.lww.com/JTO/A97, for the unadjusted Ka-
plan-Meier survival curves). Patients with a risk score of 1
were similar to those with a score of 0, both had a mortality
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FIGURE 1. Adjusted survival curves for the
nine combinations of the top two single-
nucleotide polymorphism (SNP) genotypes.
Each line represents one of the nine geno-
type combinations between rs3768490 and
rs1729786. Average method was used for
the multivariate adjusted curves. The black
line (CC/GG of rs3768490 and rs1729786)
was the reference group used for statistical
testing of significance. Survival probability
from 0 to 0.5 on y axis was cut for better
readability of the curves, and survival time
was truncated at 5 years post diagnosis.
TABLE 3. The Effects of Combined Genotypes on Survival in LS Non-Small Cell Lung Cancer
rs3768490 rs1729786
Total (%),
N  646a
Person-Years
of Follow-up
Dead,
N  279 HR (95% CI) Global p
CC GG 88 (13.62) 511.4 36 1.00 (reference) 9.00  104
CC AG 136 (21.05) 794.2 58 1.36 (1.03–1.80)
CC AA 48 (7.43) 286.1 24 1.73 (1.22–2.47)
AC GG 85 (13.16) 517.0 34 1.19 (0.92–1.53)
AC AG 145 (22.45) 760.7 75 1.62 (1.12–2.35)
AC AA 50 (7.74) 275.2 28 2.06 (1.35–3.14)
AA GG 44 (6.81) 295.6 9 0.53 (0.34–0.83)
AA AG 42 (6.50) 261.0 13 0.73 (0.43–1.25)
AA AA 8 (1.24) 46.5 2 0.93 (0.52–1.65)
a N  646 (1 with missing genotype in RS1729786).
HR, hazard ratio; CI, confidence interval; LS, low stage.
TABLE 4. Genotype Score-Based Prediction Model for Survival in LS Non-Small Cell Lung Cancer
Genotype
Risk Score
Total (%),
N  646a
Person-Years
of Follow-Up
Dead,
N  279 HR (95% CI) p
0 44 (6.81) 295.6 9 1.00 (reference)
1 42 (6.50) 261.0 13 1.63 (0.69–3.84) 2.67  101
2 181 (28.02) 1074.9 72 2.09 (1.04–4.21) 3.80  102
3 281 (43.50) 1554.9 133 2.89 (1.47–5.70) 2.20  103
4 98 (15.17) 561.3 52 3.83 (1.87–7.81) 2.00  104
Per score
(trend test)
1.37 (1.21–1.56) 0.0001
a N  646 (1 with missing genotype in RS1729786).
HR, hazard ratio; CI, confidence interval; LS, low stage.
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rate lower than those with higher risk scores (2); patients
with a genotype risk score of 4 had a 3.83-fold (95% CI:
1.87–7.81) higher risk of dying than those with a score of 0
(Table 4).
When comparing the adjusted survival curves (Figures
1 and 2) with unadjusted Kaplan-Meier survival curves (Sup-
plementary Figures 1 and 2), we noticed not only some
consistencies but also some differences, suggesting a need to
closely look at the model fit for the Cox proportional hazards
analysis. Our assessments demonstrated that the assumptions
of the multivariable regression models were reasonably well
approximated by the data; therefore, we believe that our
adjusted estimates provided an appropriate reflection of as-
sociations between the chosen SNPs and OS after diagnosis
of NSCLC.
DISCUSSION
Almost all patients with LS-NSCLC are treated with
surgical resection, but outcomes vary statistically from one
individual to another. The relatively homogeneous treatment
modality coupled with the highly variable outcomes suggests
the effects of host variations on surgery-induced outcomes. In
this study, we took a systematic approach and genotyped
tag-SNPs within 57 common genes from the glutathione
metabolism, DNA repair, and inflammatory response path-
ways. Our purpose was to test the roles of the key genes in
these pathways in OS of LS-NSCLC after surgical resection
and to measure the magnitude of any identified effects. Our
results showed that two tag-SNPs, rs3768490 and rs1729786,
from the GSTM5 and ABCC4 genes were significantly asso-
ciated with survival of LS-NSCLC after adjusting for poten-
tial confounding variables. Through gene-based analyses, the
survival predictive effects of GSTM5 and ABCC4 genes were
confirmed. Two additional genes, PTGS2 and GSTA2, were
identified to be significantly associated with OS of LS-
NSCLC. The fact that a significant association was observed
only from a gene-based test suggests that either combinations
of genotyped alleles or individual SNPs that were not geno-
typed may better explain the genetic associations than the
individual tag-SNPs that were genotyped. To understand the
cumulative effects of multiple variants in different genes on
survival, we constructed a cumulative risk prediction model
for OS based on the combination of the two tag-SNPs, which
could better segregate high- and low-risk patients.
Glutathione S-transferase mu 5 (GSTM5) belongs to the
family of the Mu class of glutathione-S-transferases (GSTs)
widely expressed in lung tissue. GSTs catalyze a number of
reactions between glutathione (GSH) and lipophilic com-
pounds with electrophilic centers. When the reaction forms a
covalent bond, the resultant more water-soluble GSH conju-
gate is usually no longer toxic and may be excreted.28 The
GST mu class of GST genes consists of five members,
GSTM1, GSTM2, GSTM3, GSTM4, and GSTM5, which are
arranged in tandem spanning a 97-kb region on chromosome
1p13.29–31 GSTM5 is a less well-studied family member and
to our knowledge, associations between polymorphisms in
this gene and lung cancer survival have not been reported.
The tag-SNP rs3768490 that showed a significant association
with OS in this study is intronic, and its functional signifi-
cance is not yet understood; it remains possible that the
significance arises only through its linkage disequilibrium
with other functional SNPs.
ATP-binding cassette subfamily C member 4 (ABCC4)
is a member of the multidrug resistance protein family, which
transports glutathione conjugates across the cell membrane.35
ABCC4 is localized in the apical luminal membrane of
polarized epithelial cells of several excretion organs (e.g.,
liver, intestine, and kidney). Evidence shows that ABCC4 has
very important roles in the pharmacogenetics of cancer33; for
example, in childhood acute lymphoblastic leukemia (T-1393C
and A934C [Lys304Asn] polymorphisms)34 and with cyclo-
phosphamide-induced adverse drug reactions in patients with
breast cancer (rs9561778).35 Among the 63 tag-SNPs analyzed
from ABCC4 in our study, rs1729786 was found to be signifi-
cantly associated with OS of LS- NSCLC; similar to rs3768490,
rs1729786 is intronic, and its functional significance needs to be
further elucidated.
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FIGURE 2. Adjusted survival curves for
genotype risk scores. Adjusted survival
curves were created for the patients with
genotype risk scores of 0/1, 2, 3, and 4
using the average method. The adjusted
variables included age at diagnosis, lung
cancer stage, surgery subtype, and adjuvant
therapy. Patients with a score of 0 were not
statistically different from those with a score
of 1, and the 2 groups were therefore com-
bined and used as reference (black line).
Survival probability from 0 to 0.5 on the
y axis was cut for better readability of the
curves, and survival time was truncated at
5 years post diagnosis.
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The prostaglandin-endoperoxide synthase 2 gene
(PTGS2), encoding the COX-2 enzyme, has been found to be
overexpressed in many tumor types, including lung cancer,36
and polymorphisms in PTGS2 were also reported to be associ-
ated with lung cancer.37 The glutathione S-transferase alpha 2
gene (GSTA2) is highly polymorphic, and its function is less
investigated. GSTA2 and GSTA1 are coexpressed and form
heterodimers in most human tissues.38 Our gene-based analysis
results implied that multiple independent polymorphic markers
with weak effects, or individual SNPs that were not genotyped,
in the PTGS2 and GSTA2 genes may affect OS in LS-NSCLC.
There are several advantages in our study design, re-
sults from which contributed comprehensive and robust
knowledge to our understanding of survival after the diagno-
sis of NSCLC. First, we recruited a relatively large and
homogeneous cohort of patients, thus improved statistical
power. Second, we focused on patients with LS (stages I and
II) NSCLC with white ethnic background, which reduced the
possibility of false discovery caused by disease heterogeneity
and population stratification. Disease heterogeneity and pop-
ulation stratification are key reasons why findings from ge-
netic association studies cannot be replicated easily. Third,
we conducted both SNP- and gene-based association tests,
which improved the opportunities to detect the true associa-
tion signals for a given gene. Fourth, relatively stringent
control of the false discovery rate by the estimation of q
values improved the robustness of the positive findings. Fifth,
we generated a cumulative risk prediction model to bridge the
gap between genetic information and potential clinical appli-
cation, which points to the clinical utility of these genomic
markers in patient management.
A few points need to be addressed in further investiga-
tions. First, it is important to replicate these findings in
additional collections of patients, both within whites as a
validation and in other ethnic populations as an assessment of
whether our findings have population-specific effects. Sec-
ond, it is important to carry out functional studies to uncover
the biological mechanisms by which these genetic variants
influence patient survival. Third, it is important to understand
whether there are differential SNP effects by specific cyto-
toxic treatment agent. In this study, with only 25% of the
patients receiving chemotherapy, and with over 70% of those
receiving platinum and taxane doublets, analyses of specific
drug combinations were not adequately informative. In other
words, we would not have adequate power to evaluate the
interaction effects between genetic variations and various
drug combinations.
In summary, our results show that genetic variants in
the glutathione metabolic and inflammatory response path-
ways may influence OS after NSCLC diagnosis in a white
population. Specifically, we have found association signals
for GSTM5, ABCC4, PTGS2, and GSTA2 from SNP- and/or
gene-based analyses. The high-risk tag-SNPs in the GSTM5
and ABCC4 genes may be good combinatorial predictors of
mortality after NSCLC diagnosis. Further validation of these
SNP associations with functional characterization of their
roles in lung cancer outcomes is warranted.
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